"The lack of accurate reporting can have impacts on medical patients controlling [their] dosage, recreational consumers expecting an effect aligned with price, and trust in the industry as a whole.”
“There was no significant association between any measure of cannabis use at baseline and either transition to psychosis, the persistence of symptoms, or functional outcomes,” researchers reported.